PF-Atlas › Clinical Trials › NCT05676112

Safety of Nintedanib in Real World in China

nintedanib · Not specified

Registry ID
NCT05676112
Phase
Not specified
Status
Withdrawn
Drug / intervention
nintedanib
Sponsor
Boehringer Ingelheim
Start
2023-12-29

About this trial

nintedanib is evaluated in NCT05676112, a idiopathic pulmonary fibrosis study sponsored by Boehringer Ingelheim. Current status: Withdrawn.

View NCT05676112 on ClinicalTrials.gov →

Explore related

All nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT05676112 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.